Turning the tariff tight spot into a sweet spot
US President Trump's fresh salvo of 100 per cent tariffs on branded or patented pharmaceutical products not ‘Made in America’…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Enzene Biosciences
Enzene appoints new site lead for flagship US continuous biomanufacturing facility
Stoffregen will take responsibility for Enzene’s global biologics business and lead the final stages of work to commission the…
Enzene Biosciences launches Ranibizumab to treat neovascular AMD
Ranibizumab biosimilar is the company’s seventh biosimilar
Enzene Biosciences inaugurates R&D Center with open lab setup in Pune
The new R&D centre signals strategic growth plans, expanded capabilities and enhanced services
Enzene Biosciences launches Bevacizumab
Manufactured using Enzene Biosciences’ patented Continuous Manufacturing Process, Bevacizumab is a biosimilar to Avastin and will…
Enzene Biosciences launches Cetuximab, biosimilar of cancer drug Erbitux
Cetuximab is a therapeutic chimeric monoclonal antibody that is used as a targeted therapy for metastatic colorectal cancer (mCRC)…
Enzene Biosciences begins commercial supply of its biosimilar of Adalimumab
This is the company’s fourth biosimilar launch in recent times
Enzene Biosciences raises $50 million to boost manufacturing capabilities and grow in global markets
The funding round is led by Alkem Laboratories and new investors, Eight Roads Ventures and F-Prime Capital